Combining cetuximab (Erbitux) with standard therapy improved the resectability of previously inoperable liver metastases of colorectal cancer.
Progression-free survival improved in patients with advanced neuroendocrine tumors when everolimus rather than placebo was used in combination with octreotide long-acting repeatable.
Higher doses of yttrium-90 (Y-90) than previously used in intra-arterial radioembolization to treat persons with liver tumors provide results when chemotherapies have failed.
The presence of high levels of a particular protein in tumors drives metastasis, providing a valuable biomarker for predicting the spread of cancer.
A 35-year-old woman presents with a one-day history of lower-right abdominal pain, setting the stage for chemotherapy for metastatic colorectal cancer
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Primary Care Physicians Surveyed on Breast Cancer Screening Practices
- Low Acculturated Latina Women Reported Breast Cancer Treatment Experience Differently Than Other Groups
- Cost and Complication Rates Differ Among Early Breast Cancer Treatment Options
- Distress Management Tool Gets an Update, Patient Version
- PSA Screening Rates Level Off in United States
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|